Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital.

The purpose of the study was to analyze the first-year cost ofhematopoietic stem cell transplantation (HSCT) program for the treatment of adult patients with acute myeloid leukemia (AML) at King Chulalongkorn Memorial Hospital (KCMH). The present retrospective study was carried out on 67 AML patients treated with bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) at KCMH during the period of 1994 to 2005. The actual total one-year cost from the provider perspective were determined by the reviewing medical records for medical care costs (MCCs) and by adjusting data from the reports of annual cost analysis of KCMH for routine services costs (RSCs). All costs were converted to 2006 values using the Thai consumer price indices. It was found that the full cost of allogeneic HSCT (allo-HSCT) and autologous HSCT (auto-HSCT) in the first year of the program was $22,592.85 and $24,171.25 per case respectively. Cost-effective appraisal, comparing with chemotherapy, need to be studied further.

Situation analysis of occupational and environmental health laboratory accreditation in Thailand.

The objective of this study was to analyze the current situation of laboratory accreditation (LA) in Thailand, especially on occupational and environmental health. The study integrated both quantitative and qualitative approaches. The response rate of the quantitative questionnaires was 54.5% (226/415). The majority of the responders was environmental laboratories located outside hospital and did not have proficiency testing. The majority used ISO 9000, ISO/IEC 17025 or ISO/ EEC Guide 25, and hospital accreditation (HA) as their quality system. However, only 30 laboratories were currently accredited by one of these systems. Qualitative research revealed that international standard for laboratory accreditation for both testing laboratory and calibration laboratory was ISO/IEC Guide 25, which has been currently revised to be ISO/IEC 17025. The National Accreditation Council (NAC) has authorized 2 organizations as Accreditation Bodies (ABs) for LA: Thai Industrial Standards Institute, Ministry of Industry, and Bureau of Laboratory Quality Standards, Department of Medical Sciences, Ministry of Public Health. Regarding LA in HA, HA considered clinical laboratory as only 1 of 31 items for accreditation. Obtaining HA might satisfy the hospital director and his management team, and hence might actually be one of the obstacles for the hospital to further improve their laboratory quality system and apply for ISO/IEC 17025 which was more technically oriented. On the other hand, HA may be viewed as a good start or even a pre-requisite for laboratories in the hospitals to further improve their quality towards ISO/IEC 17025. Interviewing the director of NAC and some key men in some large laboratories revealed several major problems of Thailand's LA. Both Thai Industrial Standards Institute and Bureau of Laboratory Quality Standards did not yet obtain Mutual Recognition Agreement (MRA) with other international ABs. Several governmental bodies had their own standards and accreditation systems, and did not accept other bodies' standards and systems. This put a burden to private laboratories because they had to apply and get accredited from several governmental bodies, but still had to apply and get accredited from international ABs especially for those dealing with exports. There were only few calibration laboratories, not enough for supporting the calibration required for the equipment in testing laboratories' LA. Purchasing proficiency testing specimens from abroad was very expensive, and often got into troubles with the customs duty procedures. The authors recommend some strategies and activities to improve laboratory accreditation in Thailand. Improvement in occupational and environmental health laboratories would essentially be beneficial to laboratory accreditation of other areas such as clinical laboratory.

Cost-benefit analysis of hepatitis a vaccination in Thailand.

We constructed a decision model to simulate costs and benefits for persons in the context of hepatitis A prevention. Three strategies were compared: i) no intervention; ii) vaccination against hepatitis A without screening; iii) vaccination against hepatitis A for those susceptible after screening for anti-HAV. We divided the population into 3 age groups : 3-11 years, 12-18 years and 19-40 years. Data regarding the cost of treatment and vaccination were obtained from the King Chulalongkorn Memorial Hospital. Relevant probabilities were obtained from published literature and expert opinion. At the present incidence of hepatitis A infection, in all age groups examined, the net benefits of a universal no-intervention strategy were higher than those of either vaccination (intervention) strategy. The cost of vaccination without screening in the 3-11-year and 12-18-year groups would equal the benefit if the incidence rates amounted to approximately 138 and 212 infected individuals per 100,000, respectively, that of vaccination with screening at incidence rates of about 200 and 260 infected persons per 100,000, respectively. In the 19-40-year group, the cost incurred by vaccination either with or without screening would equal the benefit at an incidence rate above 450 infected individual per 100,000. For the benefits to outweigh the estimated vaccination costs at present the vaccine is still too expensive. The cost of vaccination without screening in the 3-11-year group would equal the benefit if the cost of vaccine was about 586 baht/2 doses (293 baht/dose), and about 500 baht/2 doses (250 baht/dose) in the 12-18-year group. Likewise, because of the cost of vaccine, it would not be cost-beneficial in the 19-40-year group both with and without screening, and neither would it be in the 3-11-year and 12-18-year groups including screening. According to current standards, under the conditions of the present study the benefit of hepatitis A vaccination administered to the general population between the age of 3 and 40 years in Thailand does not justify the expenses incurred. Major changes in hepatitis A incidence, anti-HAV seroprevalence, vaccine cost or the treatment outcome would be required to potentially render either intervention strategy cost beneficial.